An effective and better strategy for reducing body burden of radiostrontium.
In this study we have examined the effect of different calcium salts, Ca gluconate (CaG), Ca lactate (CaL), Ca carbonate (CaC) and Ca phosphate (CaP), on the clearance of radiostrontium (*Sr) administered either intraperitoneally (ip) (*Sr-ip group) or orally (*Sr-oral group) in rats. The influence of these Ca salts was examined in a group of animals administered *Sr ip, while the effect of three Ca salts (CaG, CaL and CaP) was studied in another group of rats given *Sr orally and compared with that of Ca alginate (CaA), normally advised for *Sr decorporation. Rats from both groups were subdivided into control and four experimental subgroups and were housed individually. The experimental subgroups were given the respective Ca salts (elemental Ca = 9 mg/rat/day) 2 h post 85Sr, and thereafter once daily. In the *Sr-ip group, CaG was administered ip while the other Ca salts were given orally. In the *Sr-oral group all Ca salts were administered orally. In addition, the diet of all the experimental subgroups was supplemented with the respective Ca salts to 2% elemental Ca. The whole-body retention (WBR) of *Sr in animals treated with Ca salts was found to be significantly reduced from 50-60% at 24 h to 20-30% at the end of 15 days compared with 70-80% at 24 h to 50-60% at the end of 15 days in the untreated control animals. The results strongly suggest that CaA could be replaced by any of the commonly used Ca salts for curtailing the WBR of *Sr. CaG which was administered ip, in the *Sr-ip group, was found to be more effective in reducing the WBR of *Sr.
Jagtap
V S
VS
Laboratory Nuclear Medicine Section (Isotope Group, BARC), Tata Memorial Hospital Annexe, Parel, Mumbai 400 012, India.
Sonawane
V R
VR
Pahuja
D N
DN
Rajan
M G R
MG
Rajashekharrao
B
B
Samuel
A M
AM
D000284:Administration, Oral; D000818:Animals; D000931:Antidotes / Q000008:administration & dosage / Q000493:pharmacokinetics; D001822:Body Burden; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000493:pharmacokinetics; D017610:Calcium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D002125:Calcium Gluconate / Q000008:administration & dosage / Q000493:pharmacokinetics; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000493:pharmacokinetics; D002136:Calcium, Dietary / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007274:Injections, Intraperitoneal; D007773:Lactates / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D013326:Strontium Radioisotopes / Q000378:metabolism* / Q000633:toxicity; D013997:Time Factors
D000931:Antidotes; D017610:Calcium Compounds; D002130:Calcium Phosphates; D002136:Calcium, Dietary; D007773:Lactates; D013326:Strontium Radioisotopes; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C110051:calcium lactate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; D002119:Calcium Carbonate; C485829:calcium phosphate, dibasic, anhydrous; D002125:Calcium Gluconate